Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn F Pierce

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Thrombosis and Haemostasis|December 23, 2016
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia BK John Pasi, Kathelijn Fischer, Margaret Ragni, et al.
Research and Practice in Thrombosis and Haemostasis|April 16, 2025
Development of a novel gene editing lexicon for hemophilia: methodology and resultsCraig M Kessler, Leonard A Valentino, Courtney D Thornburg, et al.
Blood|November 24, 2011
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsAmy D Shapiro, Margaret V Ragni, Leonard A Valentino, et al.
British Journal of Haematology|September 12, 2014
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG studyJerry S Powell, Shashikant Apte, Hervé Chambost, et al.
The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.
Blood|November 15, 2013
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia AJohnny Mahlangu, Jerry S Powell, Margaret V Ragni, et al.
Blood|February 21, 2020
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and miceEkta Seth Chhabra, Tongyao Liu, John Kulman, et al.
The New England Journal of Medicine|December 6, 2013
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia BJerry S Powell, K John Pasi, Margaret V Ragni, et al.
Nature Medicine|February 14, 2006
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseCatherine S Manno, Glenn F Pierce, Valder R Arruda, et al.
Expert Review of Hematology|March 15, 2023
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and fundingMargaret V Ragni, Guy Young, Glaivy Batsuli, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|December 23, 2016
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia BK John Pasi, Kathelijn Fischer, Margaret Ragni, et al.
Research and Practice in Thrombosis and Haemostasis|April 16, 2025
Development of a novel gene editing lexicon for hemophilia: methodology and resultsCraig M Kessler, Leonard A Valentino, Courtney D Thornburg, et al.
Blood|November 24, 2011
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsAmy D Shapiro, Margaret V Ragni, Leonard A Valentino, et al.
British Journal of Haematology|September 12, 2014
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG studyJerry S Powell, Shashikant Apte, Hervé Chambost, et al.
The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.
Blood|November 15, 2013
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia AJohnny Mahlangu, Jerry S Powell, Margaret V Ragni, et al.
Blood|February 21, 2020
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and miceEkta Seth Chhabra, Tongyao Liu, John Kulman, et al.
The New England Journal of Medicine|December 6, 2013
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia BJerry S Powell, K John Pasi, Margaret V Ragni, et al.
Nature Medicine|February 14, 2006
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseCatherine S Manno, Glenn F Pierce, Valder R Arruda, et al.
Expert Review of Hematology|March 15, 2023
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and fundingMargaret V Ragni, Guy Young, Glaivy Batsuli, et al.
Pageof 10